Charles Schwab Investment Management Inc. Boosts Stake in Catalent, Inc. (NYSE:CTLT)

Charles Schwab Investment Management Inc. boosted its holdings in Catalent, Inc. (NYSE:CTLT - Free Report) by 1.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,560,470 shares of the company's stock after purchasing an additional 24,157 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.86% of Catalent worth $70,112,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Gladius Capital Management LP purchased a new stake in shares of Catalent in the third quarter worth about $28,000. GAMMA Investing LLC bought a new position in shares of Catalent during the 4th quarter valued at approximately $33,000. Cary Street Partners Investment Advisory LLC grew its holdings in shares of Catalent by 1,162.3% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company's stock valued at $35,000 after purchasing an additional 709 shares in the last quarter. Rakuten Securities Inc. bought a new stake in Catalent in the fourth quarter worth $46,000. Finally, Federated Hermes Inc. purchased a new stake in Catalent during the fourth quarter valued at $46,000.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Royal Bank of Canada reissued a "sector perform" rating and issued a $63.50 price objective on shares of Catalent in a research note on Tuesday, February 20th. Barclays upped their price objective on Catalent from $45.00 to $47.00 and gave the company an "equal weight" rating in a research report on Thursday, January 25th. StockNews.com started coverage on Catalent in a report on Monday. They issued a "sell" rating for the company. Stephens reissued an "equal weight" rating and set a $63.50 target price on shares of Catalent in a research report on Thursday, April 4th. Finally, UBS Group restated a "neutral" rating and issued a $63.50 price target (up from $58.00) on shares of Catalent in a research report on Tuesday, February 6th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $52.46.

Catalent Trading Up 0.2 %

CTLT stock traded up $0.09 during mid-day trading on Wednesday, reaching $55.61. The company had a trading volume of 766,487 shares, compared to its average volume of 2,412,987. The company has a market capitalization of $10.06 billion, a PE ratio of -9.12, a price-to-earnings-growth ratio of 6.73 and a beta of 1.18. The firm has a 50 day moving average of $56.24 and a 200 day moving average of $49.84. Catalent, Inc. has a 12 month low of $31.50 and a 12 month high of $60.20. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.51 and a quick ratio of 1.77.

Catalent (NYSE:CTLT - Get Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.21 by ($0.36). The firm had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.11 billion. Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. On average, equities analysts predict that Catalent, Inc. will post 0.28 earnings per share for the current fiscal year.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.